Filing Flows › Kyntra Bio (KYNB) › Next earnings date
Kyntra Bio (KYNB) earnings on Nov 9, 2026: what to expect
Kyntra Bio (KYNB) is expected to report earnings on Nov 9, 2026 (estimated), tomorrow, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$3.33 (−$3.75 to −$2.92, 2 estimates) on revenue of $1.7M, against $49.61 and $1.1M a year ago. It beat the EPS estimate in 50% of the quarters on record; Filing Flows' model gives it a 65% chance of beating next time.
What to watch
Last quarter (Q1 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS $26.05 on revenue of $1.5M, against the analysts' −$3.33.
The last report
Kyntra Bio reported revenue of $3.7M for the first quarter 2026 (+36% Y/Y), net loss $15.2M: Drug Product Revenue $3.5M, Development and Other Revenue $246K. How it makes money → · Every quarter →
Kyntra Bio's latest quarter
Kyntra Bio, Q1 2026: revenue $3.7M (+36% year over year), operating margin -369.7%, net loss $15.2M, operating cash flow −$13.9M. The chart follows the revenue to costs, profit and cash.
Questions
When does KYNB report earnings?
Kyntra Bio is expected to report on Nov 9, 2026 (estimated).
What are analysts expecting from Kyntra Bio?
EPS of −$3.33 and revenue of $1.7M for the quarter.
Does Kyntra Bio usually beat earnings?
It beat the consensus EPS estimate in 50% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.